ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
ProQR Therapeutics N.V.NASDAQ: PRQR
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI falls 2.8% from a year ago
Accumulated OCI stood at €28.33M at the end of Q1 FY2026, down 2.8% from a year earlier and down 1.2% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.
Context
- Accumulated OCI amounted to 28.6% of total assets at the end of Q1 FY2026, up 10.8 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -2.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
EUR · from the balance sheet
- Latest · FY2025
- 28.68M EUR
- Year-over-year change
- +3.9%
- 4-year CAGR
- -1.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.68M | +3.9% |
| FY2024 | 2024-12-31 | 27.6M | -3.8% |
| FY2023 | 2023-12-31 | 28.69M | -5.2% |
| FY2022 | 2022-12-31 | 30.26M | -0.1% |
| FY2021 | 2021-12-31 | 30.3M | — |
Accumulated OCI vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -2.8% is the 3rd highest of 9, against a peer median of -55.7%.
- Accumulated OCI amounts to 28.6% of total assets for PRQR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | A$47.26M AUD | +7.2% | +22.0% | 32.1% | |
| Mar 2026 | €28.33M EUR | -2.8% | -1.8% | 28.6% | |
| Mar 2026 | $246K USD | -43.7% | — | 0.1% | |
| Mar 2026 | $212K USD | -44.6% | — | 0.0% | |
| Mar 2026 | $2K USD | -66.7% | +35.7% | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | -$183K USD | -525.6% | — | 0.0% | |
| Mar 2026 | -$253.73K USD | -114.0% | +39.1% | 0.1% | |
| Mar 2026 | -$12.57M USD | +17.8% | — | 31.0% | |
| Peer median (excluding PRQR) | — | -55.7% | +35.7% | 0.0% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.52M | 94.78M | 131.37M | 149.41M | 92.37M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 823K | 56.25M | 1.4M | 2.03M | 5.08M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 823K | 982K | 0 | 2.03M | 0 |
| Total Current Assets | 191.48M | 154.46M | 133.65M | 153.85M | 100.08M |
| Property, Plant & Equipment (Net) | 17.47M | 16.24M | 18.67M | 14.11M | 12.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 629K | 621K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 1 | 0 | 0 | 0 |
| Total Non-current Assets | 18.1M | 16.86M | 18.67M | 14.11M | 12.62M |
| Total Assets | 209.58M | 171.32M | 152.31M | 167.96M | 112.71M |
| Account Payables | 191K | 392K | 1.7M | 16K | 297.87K |
| Short-term Debt | 4.77M | 2.5M | 1.78M | 4.58M | 4.44M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 22.72M | 0 | 17.54M |
| Other Current Liabilities | 19.87M | 15.59M | 11.58M | 31.26M | 10.14M |
| Total Current Liabilities | 27.6M | 20.99M | 37.78M | 38.9M | 32.43M |
| Long-term Debt | 39.32M | 4.27M | 4.74M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 48.79M | 0 | 21.38M |
| Other Non-current Liabilities | 14.69M | 65.57M | 0 | 29.43M | 0 |
| Total Non-current Liabilities | 68.75M | 83.65M | 68.81M | 40.5M | 30.93M |
| Total Liabilities | 96.35M | 104.64M | 106.59M | 79.4M | 63.36M |
| Common Stock | 3M | 3.37M | 3.72M | 4.31M | 4.31M |
| Retained Earnings | (317.77M) | (379.11M) | (442.8M) | (427.16M) | (467.31M) |
| Accumulated OCI | 30.3M | 30.26M | 28.69M | 27.6M | 28.68M |
| Other Stockholders Equity | 1 | 1 | 0 | 0 | 0 |
| Minority Interest | (604K) | (384K) | 0 | 0 | 0 |
| Total Equity | 113.23M | 66.68M | 45.72M | 88.56M | 49.35M |
| Total Debt | 60.37M | 21.97M | 21.8M | 17.22M | 13.99M |
| Net Debt | (127.15M) | (72.8M) | (109.57M) | (132.19M) | (78.39M) |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.